Routine Care

ApprovedSmall molecule

UUniversity of California, Los Angeles

Routine Care is one of 95 small molecule programs targeting Arrhythmia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArrhythmiaActive, not recruiting

Peripheral NeuropathyActive, not recruiting

Type 2 DiabetesActive, not recruiting

ArrhythmiaPhase 3

Active, not recruiting

Peripheral NeuropathyPreclinical

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Routine Care

UUniversity of California, Los Angeles

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

Glargine

Eli Lilly

Preclinical

8 5

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 6

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

1 9

GLP-1

RRigshospitalet, Denmark

Preclinical

1 10

Dipeptidyl Peptidase-4 Inhibitors

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes1 trial

INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes

Completed·OOhio University·Phase 4·NCT01087567·23 enrolled

EGFR1 trial

A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin Reactions

Unknown status·FFirst People's Hospital of Hangzhou·Phase 2·NCT04242927·36 enrolled

Arrhythmia1 trial

Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias

Unknown status·UUniversity of California, Los Angeles·Phase 3·NCT01013714·40 enrolled

Peripheral Neuropathy1 trial

ACUpuncture in Diabetic Peripheral Neuropathy

Completed·BBenno Brinkhaus·N/A·NCT03755960·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Routine Care. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Routine Care compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Routine Care. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of California, Los Angeles

Routine Care

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes1 trial

EGFR1 trial

Arrhythmia1 trial

Peripheral Neuropathy1 trial

References

Drug Info

Quick Facts

Related News